Zegenex has been named to Technical.ly's RealLIST Startups 2026, the publication's yearly list of Pittsburgh's most promising early-stage companies.
Technical.ly's RealLIST Startups highlights early-stage companies in the region that are positioned to keep making an impact in their markets and communities. To qualify, a company must have been founded within the past three years, must not have had a significant exit, and must be headquartered in the Pittsburgh area. Technical.ly's editors evaluate candidates on societal impact, founder experience, capital raised, and community involvement.
Z
About ZegeneX Research Community
Translational Innovation from the University of Pittsburgh
ZegeneX Therapeutics is advancing first-in-class small-molecule regenerative wound healing therapeutics licensed from the University of Pittsburgh to eliminate avoidable diabetic amputations worldwide.
